1

T. Lebret et al. Supplementary material

Appendix 2. Items of the practitioner, nurse and patient questionnaires

Practitioner questionnaire

At patient inclusion

  1. Patient conformity with selection criteria
  2. Demographics and status: age, gender, body weight, height, oral and dental hygiene (visit to dentist during last 6 months), Eastern Cooperative Oncology Group performance status (ECOG PS)
  3. Primary tumour: date of diagnosis, site
  4. Bone metastases: date of diagnosis, single/multiple, sites
  5. Non osseous metastases: presence, sites
  6. Cancer treatment: treatments, administration mode, where administered
  7. Laboratory tests: calcium, phosphates, magnesium, creatinine, creatinine clearance, calcium and/or vitamin D supplementation
  8. ZOL prescription: dose, infusion time, schedule, date of 1st Z infusion within the framework of the study
  9. Adverse effects (whether severe or not) reported to practitioner by patient during earlier ZOL administration.
  10. Prior prescriptions for biphosphonates (dates, scheduled date of first ZOL administration at home)

At 6- and 12-month follow-up visits

  1. Status: body weight, oral and dental hygiene (invasive dental procedure since last visit), ECOG PS
  2. Metastatic disease progression: new bone metastases, skeletal events, overall progression
  3. Laboratory tests: see point 7 (patient inclusion)
  4. ZOL prescription: number of infusions since inclusion, adjustments of dose or infusion time due to impaired renal function , changes in interval between infusions
  5. Adverse effects (whether severe or not)

On early withdrawal of ZOL, date and reason for withdrawal

Nurse questionnaire

At first infusion

  1. Employer: Hospital at Home, Health services firm, Independent worker
  2. Main contact person: Hospital consultant, Community practitioner, Hospital nurse
  3. Satisfaction with relationship with the hospital department in charge of patient
  4. Treatment schedule: Venous access (peripheral, external catheter, implantable device), ZOL dose, infusion time, use of portable infusion delivery system, system rinse (20 ml of saline at end of infusion)
  5. Patient hydration before ZOL infusion
  6. Adverse effects during or after the infusion: nausea/vomiting, headache, flu-like symptoms, pain (bone, joint and/or muscle), fever, fatigue, shivering, local reaction at infusion site (redness, swelling, and/or pain, extravasation), other
  7. Most recent laboratory test results: calcium, phosphates, magnesium, creatinine, creatinine clearance
  8. Demographics: age, gender

Topics brought up by the patient during the infusion: his/her illness, ZOL treatment, ongoing cancer therapy, other

Will regular home visits to administer ZOL promote a good patient-nurse relationship

Satisfaction with overall set-up for infusing ZOL to patient

Technical ease of ZOL administration (product preparation, administration)

At 4 and 8 months

See items 1 to 8 above.

Number of ZOL infusions since first infusion.

Patient questionnaire

At 6 and 12 months

  1. Overall satisfaction with at home ZOL therapy
  2. Any preference for therapy in hospital, with reasons
  3. First person contacted in case of problem with at home therapy
  4. Advantages of at home ZOL therapy
  5. Would you recommend at home ZOL therapy